352 related articles for article (PubMed ID: 32228232)
1. TGF-beta: a master immune regulator.
Larson C; Oronsky B; Carter CA; Oronsky A; Knox SJ; Sher D; Reid TR
Expert Opin Ther Targets; 2020 May; 24(5):427-438. PubMed ID: 32228232
[No Abstract] [Full Text] [Related]
2. Therapeutic targeting of TGF-β in cancer: hacking a master switch of immune suppression.
van den Bulk J; de Miranda NFCC; Ten Dijke P
Clin Sci (Lond); 2021 Jan; 135(1):35-52. PubMed ID: 33399850
[TBL] [Abstract][Full Text] [Related]
3. Blockade of TGF-β signaling: a potential target for cancer immunotherapy?
Ungefroren H
Expert Opin Ther Targets; 2019 Aug; 23(8):679-693. PubMed ID: 31232607
[No Abstract] [Full Text] [Related]
4. Multifunctional nanodrug performs sonodynamic therapy and inhibits TGF-β to boost immune response against colorectal cancer and liver metastasis.
Huang S; Ding D; Lan T; He G; Ren J; Liang R; Zhong H; Chen G; Lu X; Shuai X; Wei B
Acta Biomater; 2023 Jul; 164():538-552. PubMed ID: 37037269
[TBL] [Abstract][Full Text] [Related]
5. Regulatory (FoxP3
Koh J; Hur JY; Lee KY; Kim MS; Heo JY; Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Sci Rep; 2020 Nov; 10(1):18994. PubMed ID: 33149213
[TBL] [Abstract][Full Text] [Related]
6. TGF-β and Cancer Immunotherapy.
MaruYama T; Chen W; Shibata H
Biol Pharm Bull; 2022; 45(2):155-161. PubMed ID: 35110501
[TBL] [Abstract][Full Text] [Related]
7. TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy.
Yi M; Li T; Niu M; Wu Y; Zhao Z; Wu K
Front Immunol; 2022; 13():1061394. PubMed ID: 36601124
[TBL] [Abstract][Full Text] [Related]
8. Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models.
Sow HS; Ren J; Camps M; Ossendorp F; Ten Dijke P
Cells; 2019 Apr; 8(4):. PubMed ID: 30959852
[TBL] [Abstract][Full Text] [Related]
9. Roles of TGF-β signaling pathway in tumor microenvirionment and cancer therapy.
Zhao H; Wei J; Sun J
Int Immunopharmacol; 2020 Dec; 89(Pt B):107101. PubMed ID: 33099067
[TBL] [Abstract][Full Text] [Related]
10. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.
Mushtaq MU; Papadas A; Pagenkopf A; Flietner E; Morrow Z; Chaudhary SG; Asimakopoulos F
J Immunother Cancer; 2018 Jul; 6(1):65. PubMed ID: 29970158
[TBL] [Abstract][Full Text] [Related]
11. TREM2: Keeping Pace With Immune Checkpoint Inhibitors in Cancer Immunotherapy.
Qiu H; Shao Z; Wen X; Jiang J; Ma Q; Wang Y; Huang L; Ding X; Zhang L
Front Immunol; 2021; 12():716710. PubMed ID: 34539652
[TBL] [Abstract][Full Text] [Related]
12. Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor.
Bai X; Yi M; Jiao Y; Chu Q; Wu K
Onco Targets Ther; 2019; 12():9527-9538. PubMed ID: 31807028
[TBL] [Abstract][Full Text] [Related]
13. The roles of TGF-β and VEGF pathways in the suppression of antitumor immunity in melanoma and other solid tumors.
Bu MT; Chandrasekhar P; Ding L; Hugo W
Pharmacol Ther; 2022 Dec; 240():108211. PubMed ID: 35577211
[TBL] [Abstract][Full Text] [Related]
14. Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to Therapy.
Shklovskaya E; Rizos H
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32992658
[TBL] [Abstract][Full Text] [Related]
15. Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy.
Mortensen REJ; Holmström MO; Lisle TL; Hasselby JP; Willemoe GL; Met Ö; Marie Svane I; Johansen J; Nielsen DL; Chen IM; Andersen MH
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36948507
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint blockade combined with IL-6 and TGF-β inhibition improves the therapeutic outcome of mRNA-based immunotherapy.
Bialkowski L; Van der Jeught K; Bevers S; Tjok Joe P; Renmans D; Heirman C; Aerts JL; Thielemans K
Int J Cancer; 2018 Aug; 143(3):686-698. PubMed ID: 29464699
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulatory TGF-β Signaling in Hepatocellular Carcinoma.
Chen J; Gingold JA; Su X
Trends Mol Med; 2019 Nov; 25(11):1010-1023. PubMed ID: 31353124
[TBL] [Abstract][Full Text] [Related]
18. Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy.
Song Y; Li Z; Xue W; Zhang M
Immunotherapy; 2019 Apr; 11(6):515-529. PubMed ID: 30860441
[TBL] [Abstract][Full Text] [Related]
19. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors.
Pitt JM; Vétizou M; Daillère R; Roberti MP; Yamazaki T; Routy B; Lepage P; Boneca IG; Chamaillard M; Kroemer G; Zitvogel L
Immunity; 2016 Jun; 44(6):1255-69. PubMed ID: 27332730
[TBL] [Abstract][Full Text] [Related]
20. Identification of inhibitory immune checkpoints and relevant regulatory pathways in breast cancer stem cells.
Shi H; Yang Y
Cancer Med; 2021 Jun; 10(11):3794-3807. PubMed ID: 33932112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
